alteon inc. +300% kennt die jemand - 500 Beiträge pro Seite

[getri]

Ich habe mal 100 Stck. gekauft.
Leider habe ich keine Ahnung was das für Dinger sind.
Grüße Getri

[habkeingeld]

hi gerti
zu Alteon !


Alteon Inc. is engaged in the discovery and development of new pharmaceutical products for the treatment of
cardiovascular and renal disease and other disorders of diabetes and aging. The Company`s proprietary
technology focuses on Advanced Glycosylation End products (A.G.E.s), formed as a result of circulating blood
glucose reacting with proteins. The Company`s current research and drug development focused on A.G.E.
technology takes three directions: the prevention or inhibition of A.G.E. formation, the breaking of A.G.E.
cross-links between proteins in order to prevent or reverse damage, and the reduction of the A.G.E. burden
through a novel class of anti-hyperglycemic agents.

MARK NOVITCH, MD, Chairman,

joined the George Washington University Medical Center in 1994 as Professor of Health Care Sciences
and in 1997 became Adjunct Professor. He
retired as Vice Chairman and Chief
Compliance Officer of The Upjohn Company in
1993. At Upjohn (now Pharmacia & Upjohn,
Inc.) he was responsible for pharmaceutical
quality control, regulatory affairs, corporate
planning, legal, government affairs and public
relations.

Before joining Upjohn in 1985, Dr. Novitch was
Deputy Commissioner of the U.S. Food and Drug Administration and
served as Acting Commissioner in 1983-84. Earlier he served in the
U.S. Department of Health, Education and Welfare. He is a graduate of
Yale University and New York Medical College and held staff positions
at Peter Bent Brigham Hospital and Harvard Medical School.

Dr. Novitch completed a five-year term as President of the United
States Pharmocopeial Convention in 1995 and is serving an additional
five-year term as Trustee and Past President. He is a member of
several voluntary and corporate boards of directors. He and his family
reside in Washington D.C.

und hier noch einige zahlen

Monday November 13, 12:32 pm Eastern Time

Press Release

SOURCE: Alteon Inc.

Alteon Announces Financial Results for the Third Quarter Ended September
30, 2000

RAMSEY, N.J., Nov. 13 /PRNewswire/ -- Alteon Inc. (Amex: ALT - news) announced today investment income of $418,000 and a net loss of $8,085,000 for the nine
months ended September 30, 2000. This compares to investment income of $876,000 and a net loss of $11,476,000 for the same period in 1999. The net loss applicable to
common stockholders, which includes non-cash charges for a preferred stock dividend and a stock option expense resulting from the adoption of FASB Interpretation
No. 44, was $10,267,000 or $.53 per share for the nine months ended September 30, 2000, as compared to $13,480,000 or $.71 per share for the same period in 1999.

For the three months ended September 30, 2000, Alteon had investment income of $110,000 and a net loss of $3,229,000. This compares to investment income of
$370,000 and a net loss of $2,119,000 for the same period in 1999. The net loss applicable to common stockholders, which includes non-cash charges for a preferred
stock dividend and a stock option expense resulting from the adoption of FASB Interpretation No. 44, was $3,977,000 or $.20 per share for the three months ended
September 30, 2000, as compared to $2,808,000 or $.15 per share for the same period in 1999. The net loss increased primarily as a result of increased research and
development expenses related to clinical trial costs and decreased investment income and the adoption of FASB Interpretation No. 44. Cash, cash equivalents and
short-term investments at September 30, 2000, totaled $8.6 million, which included $3.1 million received in the closing of the first tranche of a $6,235,000 private
placement of the Company`s common stock and warrants.

``We are pleased by Alteon`s recent progress across many areas,`` said Kenneth I. Moch, President and Chief Executive Officer of Alteon. ``In addition to the financing
agreement, we entered into a development relationship for Hemomax, a novel cardiovascular tissue perfusion technology. Increased interest in Alteon by the financial
community was reflected in part by the initiation of coverage by a Wall Street financial analyst. We eagerly anticipate the upcoming unblinding and reporting of results
from the Phase IIa clinical trial of ALT-711 in cardiovascular compliance.``

About Alteon

Alteon is a leader in the discovery and development of pharmaceuticals for the treatment of cardiovascular and renal diseases and other disorders of diabetes and aging,
based on slowing or reversing a fundamental pathological process caused by protein-glucose complexes called Advanced Glycosylation End-Products (A.G.E.s).

A.G.E.s ultimately form crosslinks with adjacent proteins, leading to a loss of flexibility and function in body tissues, organs and cells. This A.G.E. pathway represents
one of several pathological processes believed to be responsible for aging, including regulation of telomere length, DNA turnover, and build-up of senescent products,
among others. A.G.E.s have been shown to be causative factors in many of the complications of diabetes and age-related diseases, including cardiovascular disease,
kidney disease, nerve damage and retinopathy. Alteon`s unique approach is to inhibit or break A.G.E.s and their chemical crosslinks.

Alteon`s lead A.G.E. crosslink breaker, ALT-711, is in Phase IIa clinical testing to evaluate its effect on cardiovascular compliance, with results from this trial
anticipated near year-end. Additional indications being evaluated include non-obstructive uropathy, peritoneal dialysis and scleroderma. The company is seeking a
corporate partner to help fund the continued development of its A.G.E.-formation inhibitor, Pimagedine, based on the results of a Phase II/III trial in Type 1 diabetic
patients with progressive kidney disease. Alteon is also pursuing the development of a novel series of glucose lowering agent (GLA) compounds.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and product development, regulatory approval processes, intellectual property rights and litigation, competitive
products, ability to obtain financing, and other risks identified in Alteon`s filings with the Securities and Exchange Commission. The information contained in this press
release is accurate as of the date indicated. Actual results, events or performance may differ materially. Alteon undertakes no obligation to publicly release the result of
any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events.

More information on Alteon is available at the corporate web site, http://www.alteonpharma.com.

Alteon Inc.
Condensed Statement of Operations
(Dollars in Thousands Except Per Share Amounts)
(Unaudited)

Nine Months Ended Three Months Ended
September 30, September 30,
2000 1999 2000 1999

Investment Income $418 $876 $110 $370

Expenses:
Research and Development 4,739 9,077 1,736 1,379
General and
Administrative 3,764 3,275 1,603 1,110
Total Expenses $8,503 $12,352 $3,339 $2,489

Net Loss $(8,085) $(11,476) $(3,229) $(2,119)

Preferred Stock
Dividends 2,182 2,004 748 689

Net Loss Applicable
to Common
Stockholders $(10,267) $(13,480) $(3,977) $(2,808)

Basic Loss
Per Share to
Common Stockholders $(0.53) $(0.71) $(0.20) $(0.15)

Diluted Loss
Per Share to
Common Stockholders $(0.53) $(0.71) $(0.20) $(0.15)

Weighted Average
Common Shares
Used in Computing
Basic and Diluted
Loss Per Share 19,331,308 19,009,271 19,411,826 19,184,167

Selected Balance Sheet Data
(Dollars in Thousands)
(Unaudited)

September 30, December 31,
2000 1999

Cash and Investments $8,595 $12,370

Total Assets 10,907 15,021

Accumulated Deficit (131,763) (121,496)

Stockholders` Equity 9,008 12,827

SOURCE: Alteon Inc.

gruss habkeingeld

[getri]

Auf das schmale Brett mir die Homepage anzusehen bi ich auch gekommen. Leider kann ich kein Englisch.
Habe die Aktie aufgrund der Entwicklung gekauft.
In diesen Zeiten sind die guten Lappen ja selten.
Gruß Getri

[getri]

Übrigens ist die Aktie nicht m 300 % sondern um 700% gestiegen
freu Getri

[Zorro_Mace]

Hui...heut schiesst sie aber wieder hoch...+21,4% auf 8,50€...nur weiter so...
ZM